Venus Remedies Limited Stock Price Today (NSE: VENUSREM)
Fundamental Score
Venus Remedies Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Venus Remedies Limited share price today is ₹1535.10, down 0.67% on NSE/BSE as of 16 September 2026. Venus Remedies Limited (VENUSREM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.05K (Cr). The 52-week high for VENUSREM share price is ₹2044.30 and the 52-week low is ₹424.00. At a P/E ratio of 17.66x, VENUSREM is currently trading below its industry average P/E of 34.89x. 0
Venus Remedies Limited Share Price Chart — NSE/BSE Historical Performance
Venus Remedies Limited share price chart: 8.38% return over the past month. 52-week high ₹2044.30, 52-week low ₹424.00.
Venus Remedies Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1549.70 | ₹1569.60 | ₹1475.00 | ₹1535.10 | 38.70K (Cr) | |
| ₹1628.90 | ₹1645.00 | ₹1538.00 | ₹1545.40 | 34.83K (Cr) | |
| ₹1618.10 | ₹1655.00 | ₹1580.00 | ₹1616.30 | 16.54K (Cr) | |
| ₹1671.80 | ₹1674.60 | ₹1618.00 | ₹1624.20 | 12.80K (Cr) | |
| ₹1620.00 | ₹1700.00 | ₹1620.00 | ₹1650.20 | 25.23K (Cr) | |
| ₹1660.00 | ₹1683.70 | ₹1606.20 | ₹1625.20 | 25.27K (Cr) | |
| ₹1694.40 | ₹1724.90 | ₹1652.10 | ₹1669.40 | 17.77K (Cr) | |
| ₹1705.00 | ₹1778.80 | ₹1666.00 | ₹1694.40 | 30.62K (Cr) | |
| ₹1620.00 | ₹1701.90 | ₹1620.00 | ₹1701.90 | 28.87K (Cr) | |
| ₹1600.90 | ₹1650.00 | ₹1571.10 | ₹1620.90 | 25.25K (Cr) |
Venus Remedies Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1650.00 | ₹1778.80 | ₹1475.00 | ₹1535.10 | -6.96% | |
| ₹1567.10 | ₹1870.50 | ₹1446.90 | ₹1663.60 | +6.16% | |
| ₹1741.90 | ₹1959.00 | ₹1471.10 | ₹1581.60 | -9.20% | |
| ₹1344.10 | ₹2044.30 | ₹1344.10 | ₹1833.50 | +36.41% | |
| ₹998.90 | ₹1280.05 | ₹880.05 | ₹1280.05 | +28.15% | |
| ₹859.00 | ₹1088.80 | ₹831.10 | ₹967.40 | +12.62% | |
| ₹646.00 | ₹944.75 | ₹622.10 | ₹820.05 | +26.94% | |
| ₹831.45 | ₹837.45 | ₹664.00 | ₹672.40 | -19.13% | |
| ₹780.00 | ₹820.55 | ₹685.00 | ₹818.55 | +4.94% | |
| ₹695.30 | ₹839.90 | ₹665.30 | ₹766.10 | +10.18% | |
| ₹434.35 | ₹758.00 | ₹433.70 | ₹691.15 | +59.12% | |
| ₹445.05 | ₹488.10 | ₹432.10 | ₹434.35 | -2.40% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Venus Remedies Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Venus Remedies Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VENUSREM across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (21.11%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 17.66 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (126.19%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (35.60%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Profit Growth Track Record (21.81% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (3354.75x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 3.31)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹280.15 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Below-Average Return on Equity (0.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Limited Institutional Interest (FII+DII: 4.00%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Venus Remedies Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Venus Remedies Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Venus Remedies LimitedVenus Remedies ...Selected✓ VENUSREM • 526953 | 75.2/100 | ₹1535.10₹1535 | ₹2052.43₹2052.43 | 17.66Average 17.7 Average | 0.00%Poor 0.00% Poor | 21.11%Excellent 21.11% Excellent | 0.00Excellent 0.0 Excellent | 21.81%Excellent 21.81% Excellent | 7.02%Good 7.02% Good | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Venus Remedies Limited PE Ratio History
Historical price-to-earnings ratio for VENUSREM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹33.90 | ₹766.10 | 22.6x |
| FY 2024 | ₹21.31 | ₹318.45 | 14.9x |
| FY 2023 | ₹19.88 | ₹406.25 | 20.4x |
| FY 2022 | ₹30.86 | ₹127.85 | 4.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Venus Remedies Limited Quarterly Performance
Latest quarterly metrics for VENUSREM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
35.60%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
126.19%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
7.02%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
21.81%
Compounded annual net profit growth over 5 years
Venus Remedies Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VENUSREM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Venus Remedies Limited Financial Statements
Annual income statement, balance sheet and cash flow for Venus Remedies Limited (VENUSREM) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Venus Remedies Limited
About VENUSREM (Venus Remedies Limited)
Venus Remedies Ltd is a pioneering force in the global pharmaceutical landscape, committed to innovation and excellence in addressing critical healthcare challenges. With a steadfa...st dedication to research and development, the company focuses on developing cutting-edge solutions, particularly in the fields of antimicrobial resistance and oncology. Venus Remedies operates on a global scale, distributing its products and forging strategic partnerships to ensure accessibility to its life-saving treatments. The company's commitment to quality and patient well-being is evident in its state-of-the-art manufacturing facilities and adherence to stringent regulatory standards, positioning it as a trusted and reliable provider of pharmaceutical solutions worldwide. The company boasts a comprehensive portfolio of pharmaceutical products, catering to a wide spectrum of therapeutic areas. Venus Remedies offers a range of medications including pain relievers, antibiotics, and treatments for cardiovascular diseases. Furthermore, their product line includes gastrointestinal therapies, liver protection agents, and hormone-based treatments. Recognizing the significance of supportive care, the company also provides immunostimulating agents, iron supplements, and muscle relaxants. Venus Remedies maintains a commitment to advancing patient care by continually developing and refining its pharmaceutical offerings, ensuring that healthcare professionals have access to the tools they need to provide optimal treatment outcomes. Driven by a vision to improve global health, Venus Remedies prioritizes research and development to tackle pressing medical needs. The company's investment in innovative therapies, particularly in combating antimicrobial resistance and developing novel cancer treatments, reflects its commitment to addressing some of the most significant challenges facing the healthcare industry. By fostering a culture of scientific excellence and collaboration, Venus Remedies strives to develop groundbreaking solutions that enhance patient outcomes and improve the quality of life for individuals around the world. Their dedication to innovation and global health positions them as a leader in the pharmaceutical sector.
Company Details
Key Leadership
VENUSREM Share Price: Frequently Asked Questions
What is the current share price of Venus Remedies Limited?
Venus Remedies Limited (VENUSREM) trades at ₹1535.10 on NSE and BSE. Market cap ₹2.05K (Cr). Educational data only.
What is the P/E ratio of Venus Remedies Limited?
Venus Remedies Limited has a P/E of 17.66x vs industry average 34.89x.
What is the Bull Run score for Venus Remedies Limited?
Venus Remedies Limited has a Bull Run score of 75.2/100 based on 25+ financial parameters.
Does Venus Remedies Limited pay dividends?
Venus Remedies Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Venus Remedies Limited?
Venus Remedies Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Venus Remedies Limited?
Venus Remedies Limited has debt-to-equity of 0.00.
Is Venus Remedies Limited a good investment?
Bull Run gives Venus Remedies Limited a score of 75.2/100. This is not investment advice — consult a SEBI-registered advisor.